373 related articles for article (PubMed ID: 29082727)
1. Mechanisms of resistance to daptomycin in Staphylococcus aureus.
Gómez Casanova N; Siller Ruiz M; Muñoz Bellido JL
Rev Esp Quimioter; 2017 Dec; 30(6):391-396. PubMed ID: 29082727
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic and genotypic correlates of daptomycin-resistant methicillin-susceptible Staphylococcus aureus clinical isolates.
Kang KM; Mishra NN; Park KT; Lee GY; Park YH; Bayer AS; Yang SJ
J Microbiol; 2017 Feb; 55(2):153-159. PubMed ID: 28120188
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-Function Mutations in the Phospholipid Flippase MprF Confer Specific Daptomycin Resistance.
Ernst CM; Slavetinsky CJ; Kuhn S; Hauser JN; Nega M; Mishra NN; Gekeler C; Bayer AS; Peschel A
mBio; 2018 Dec; 9(6):. PubMed ID: 30563904
[TBL] [Abstract][Full Text] [Related]
4. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
Skiest DJ
J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
[TBL] [Abstract][Full Text] [Related]
6. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence.
Stefani S; Campanile F; Santagati M; Mezzatesta ML; Cafiso V; Pacini G
Int J Antimicrob Agents; 2015 Sep; 46(3):278-89. PubMed ID: 26143590
[TBL] [Abstract][Full Text] [Related]
7. Characterization of compensatory mutations associated with restoration of daptomycin-susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus and the role mprF mutations.
Kanesaka I; Fujisaki S; Aiba Y; Watanabe S; Mikawa T; Katsuse AK; Takahashi H; Cui L; Kobayashi I
J Infect Chemother; 2019 Jan; 25(1):1-5. PubMed ID: 30322736
[TBL] [Abstract][Full Text] [Related]
8. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
9. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
Mariani PG; Sader HS; Jones RN
J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
[No Abstract] [Full Text] [Related]
10. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
[TBL] [Abstract][Full Text] [Related]
11. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
13. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
[TBL] [Abstract][Full Text] [Related]
14. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Gomes DM; Ward KE; LaPlante KL
Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
Kelley PG; Gao W; Ward PB; Howden BP
J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
[TBL] [Abstract][Full Text] [Related]
17. dltA overexpression: A strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus.
Cafiso V; Bertuccio T; Purrello S; Campanile F; Mammina C; Sartor A; Raglio A; Stefani S
Int J Antimicrob Agents; 2014 Jan; 43(1):26-31. PubMed ID: 24183798
[TBL] [Abstract][Full Text] [Related]
18. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
Nannini E; Murray BE; Arias CA
Curr Opin Pharmacol; 2010 Oct; 10(5):516-21. PubMed ID: 20598637
[TBL] [Abstract][Full Text] [Related]
19. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.
Friedman L; Alder JD; Silverman JA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2137-45. PubMed ID: 16723576
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
[No Abstract] [Full Text] [Related]
[Next] [New Search]
